- Home
- NXTC vs APWC Comparison
NXTC vs APWC Comparison
Compare NXTC & APWC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- APWC
- Stock Information
- Founded
- NXTC 2015
- APWC 1996
- Country
- NXTC United States
- APWC Taiwan
- Employees
- NXTC N/A
- APWC N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- APWC Telecommunications Equipment
- Sector
- NXTC Health Care
- APWC Industrials
- Exchange
- NXTC Nasdaq
- APWC Nasdaq
- Market Cap
- NXTC 40.3M
- APWC 38.9M
- IPO Year
- NXTC 2019
- APWC 1997
- Fundamental
- Price
- NXTC $1.31
- APWC $1.81
- Analyst Decision
- NXTC Strong Buy
- APWC
- Analyst Count
- NXTC 2
- APWC 0
- Target Price
- NXTC $4.00
- APWC N/A
- AVG Volume (30 Days)
- NXTC 44.0K
- APWC 14.1K
- Earning Date
- NXTC 11-07-2024
- APWC 08-26-2024
- Dividend Yield
- NXTC N/A
- APWC N/A
- EPS Growth
- NXTC N/A
- APWC N/A
- EPS
- NXTC N/A
- APWC 0.16
- Revenue
- NXTC N/A
- APWC $446,624,000.00
- Revenue This Year
- NXTC N/A
- APWC N/A
- Revenue Next Year
- NXTC N/A
- APWC N/A
- P/E Ratio
- NXTC N/A
- APWC $11.13
- Revenue Growth
- NXTC N/A
- APWC 6.34
- 52 Week Low
- NXTC $1.03
- APWC $1.20
- 52 Week High
- NXTC $2.57
- APWC $2.00
- Technical
- Relative Strength Index (RSI)
- NXTC 45.61
- APWC 57.56
- Support Level
- NXTC $1.30
- APWC $1.76
- Resistance Level
- NXTC $1.60
- APWC $1.94
- Average True Range (ATR)
- NXTC 0.08
- APWC 0.13
- MACD
- NXTC 0.00
- APWC 0.00
- Stochastic Oscillator
- NXTC 12.12
- APWC 51.25
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About APWC Asia Pacific Wire & Cable Corporation Ltd. (Bermuda)
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in owning operating companies engaged in the power cable, telecommunication cable, enameled wire, and electronic cable industry. It also provides project engineering services to customers. Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.